You are here

Descriptive Observational Study ALK-2016-CPHG

Last updated on February 16, 2019

FOR MORE INFORMATION
Study Location
Centre Hospitalier Intercommunal du Pays d'Aix-Pertuis,Service de Pneumologie
Aix en Provence, , 13616 France
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
NSCLC, Crizotinib, ALK Gene Rearrangement or ROS1 Gene Rearrangement
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Age ≥ 18 years

- Locally advanced or metastatic NSCLC

- Patient ALK gene rearrangement or ROS1 gene rearrangement

- Patient having initiated in the previous 3 months or patient initiating crizotinib
treatment regardless of the line of treatment

- Patient followed up by a physician in a hospital pulmonary medicine department

- Subject of reproductive age, using an effective method of contraception

- Patient informed verbally and in writing on the study and having consented to his/her
personal data being collected within the scope of the study.

Non-inclusion criteria

- Patient included within the scope of an interventional therapeutic trial

- Patient not presenting with ALK gene rearrangement or ROS1 gene rearrangement

- Patient not available for follow-up throughout the duration of the study

- Patient deemed to be incapable of responding to the study questions for linguistic,
cognitive or organisational reasons.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Age ≥ 18 years

- Locally advanced or metastatic NSCLC

- Patient ALK gene rearrangement or ROS1 gene rearrangement

- Patient having initiated in the previous 3 months or patient initiating crizotinib
treatment regardless of the line of treatment

- Patient followed up by a physician in a hospital pulmonary medicine department

- Subject of reproductive age, using an effective method of contraception

- Patient informed verbally and in writing on the study and having consented to his/her
personal data being collected within the scope of the study.

Non-inclusion criteria

- Patient included within the scope of an interventional therapeutic trial

- Patient not presenting with ALK gene rearrangement or ROS1 gene rearrangement

- Patient not available for follow-up throughout the duration of the study

- Patient deemed to be incapable of responding to the study questions for linguistic,
cognitive or organisational reasons.

NCT03718117
Pfizer
Recruiting
Descriptive Observational Study ALK-2016-CPHG

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

ClinicalTrials.gov_Inquirie[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

ALK-positive Advanced NSCLC
NCT02511184
All Genders
18+
Years
Multiple Sites
NSCLC (Non-small Cell Lung Cancer)
NCT01639001
All Genders
18+
Years
Multiple Sites
NSCLC
NCT02382796
All Genders
20+
Years
Multiple Sites
Non Small Cell Lung Cancer, ROS1 Proto Oncogene, Crizotinib
NCT01945021
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now